A phase 2, multicenter, exploratory study, evaluating the treatment effect of surgery plus Gliadel Wafer [carmustine polifeprosan 20 wafer] in patients with metastatic brain cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2014
At a glance
- Drugs Carmustine polifeprosan 20 wafer (Primary)
- Indications Brain cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc; Eisai Medical Research; MGI Pharma
- 25 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Mar 2010 Planned end date changed from 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.